ClinicalTrials.gg
RecruitingNCT06429241Updated Jun 12, 2024

Evaluate the Distribution and Dynamic Behavior of TH-SC01 Cells in Vivo in Patients With Perianal Fistula

A Phase 1 interventional study of Mesenchymal Stem Cells (MSCs) in Anal Fistula, Complex Perianal Fistulas and Crohn's Disease, sponsored by Jiangsu Topcel-KH Pharmaceutical Co., Ltd.. Recruiting at 1 site in China. Open to participants aged 18 Years to 70 Years. Per ClinicalTrials.gov, last updated 2024-06-12.

Sponsored by Jiangsu Topcel-KH Pharmaceutical Co., Ltd. · Phase 1, Interventional, and Treatment

From the registry’s dates

  • Primary completion was expected by Nov 2024, 2 years ago, but the record still lists the study as recruiting.
  • Started Apr 2024; still recruiting 2 years 7 months later.
Phase
Phase 1
Study type
Interventional
Enrollment
8
Allocation
Not applicable
Ages
18 Years to 70 Years
Sex
All
01

Study summary

The purpose of this study is to evaluate the distribution and dynamic behavior of Nuclide labeled TH-SC01 cells in vivo in patients with perianal fistula

Read the detailed description

A Phase I clinical study evaluating the distribution and dynamic behavior of Nuclide labeled TH-SC01 cells in vivo in patients with perianal fistula

02

Conditions studied

  • Anal Fistula
  • Complex Perianal Fistulas
  • Crohn's Disease
03

In context

Rectal Fistula

169 studies on the registry are indexed under Rectal Fistula; 45 are open to participants now.

This study's planned enrollment of 8 is below the median of 66 across 115 interventional studies indexed under Rectal Fistula.

Browse Rectal Fistula studies →

Lead sponsor

Jiangsu Topcel-KH Pharmaceutical Co., Ltd. is the lead sponsor of 9 studies on the registry; 7 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 70 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Signed
  2. Subjects with Crohn\'s disease or complex perianal fistula diagnosed at least 6 months earlier according to the Chinese Consensus Opinion on the Diagnosis and Treatment of Inflammatory Bowel Diseases (Beijing, 2018).Subjects with active perianal fistula and non active luminal CD defined by a CDAI ≤ 200.
  3. For patients with perianal fistula, 1≤ the number of internal openings ≤2, and 1≤ the number of external openings ≤3, the fistula of the patient needs to be drained smoothly
  4. All subjects and their partners were not planning to have a child from screening to the end of the trial and agreed to use effective non-drug during the trial.
  5. score 0\~1, I\~II
  6. Subjects failed to respond to adequate treatment with any of the conventional antibiotics, immunomodulatory drugs (including ), anti-tumor necrosis factor-α (TNF-α) monoclonal antibodies and other biological agents.

Exclusion criteria

Exclusion Criteria:

  1. Subjects with active infection evaluated by the investigator.
  2. Subjects with Crohn\'s disease requiring immediate therapy.
  3. Subjects with abscess or collections \>2 cm.
  4. Subjects with rectal and/or anal stenosis and/or active proctitis.
  5. Subjects who treated with systemic in the 4 weeks prior to stem cells administration.
  6. Subjects with abnormal laboratory results: liver function: total \>=1.5 × , and (AST) and alanine aminotransferase (ALT) \>=2 × ULN; renal function: below 60 mL/minute calculated using Cockcroft-Gault formula or by serum creatinine \>=1.5 × upper limit of normal (ULN).
  7. Subjects with malignant tumors or a history of malignant tumors.
  8. Subjects with severe, progressive, uncontrolled hepatic, hematological, gastrointestinal (except Crohn\'s disease), endocrine, pulmonary, cardiac, neurological, psychiatric, or cerebral diseases.
  9. Serum virology test (HBeAg, antibody, antibody, Treponema pallidum antibody) positive.
  10. Subjects allergic to Human serum albumin, human lysate, gentamicin sulfate, anesthetic drug
  11. Subjects who has received stem cells therapy.
  12. Subjects who has major surgery or severe trauma within 6 months prior to the screening period.
  13. Subjects who has received any drug within 3 months prior to the screening.
  14. Subjects deemed inappropriate by the investigator to participate in this clinical trial.
  15. The female participant who is pregnant, or is lactating.
  16. Not suitable for PET/CT examination.
  17. Participants considered inappropriate to participate in this clinical trial
Terms in these criteria, in plain language(13)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

ASA physical status

The anaesthetists’ scale of health before surgery: I is healthy, II has a mild illness that is under control, III a severe one, IV a severe illness that is a constant threat to life. V and VI are used for the critically ill and for organ donors.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
8 participants (estimated)

Study arms

  • Experimental
    MSCs treatment group

    Intralesional injection of expanded human umbilical cord-derived mesenchymal stem cells suspension.

    Biological: Mesenchymal Stem Cells (MSCs)

Interventions

  • BiologicalMesenchymal Stem Cells (MSCs)

    single dose injection (120 million cells)

06

What researchers measure

Primary outcomes

  1. Standardized uptake value

    Standardized values of organs or tissues after PET/CT imaging after local injection in patients with perianal fistula

    Time frame: 8-12 hour、32-36 hour、56-60 hour、104-108 hour、152-156 hour,296-300 hour

Secondary outcomes

  1. Effectiveness endpoint:Proportion of subjects with clinically significant effect at week 24 after local injection

    Change from baseline in pain score (VAS score).Total score ranges from 0 to 10. Higher score means more pain.

    Time frame: Week 1,Week 4,Week 24

  2. Safety endpoint: Treatment-related adverse events/adverse reactions, serious adverse events/serious adverse events

    All subjects were observed for any adverse events/reactions or serious adverse events/reactions that occurred during the clinical trial, including but not limited to clinically significant abnormal changes in clinical symptoms, physical examination, vital signs examination, laboratory examination, 12-lead electrocardiogram examination, etc. The clinical features, severity, occurrence time, end time, treatment and outcome of the disease should be recorded, and the correlation between the disease and the investigational drug should be determined.

    Time frame: Week 1,Week 4,Week 24,Month 24

  3. Radiation exposure: Uptake rate (%ID), absorbed dose, and systemic effective dose in vital organs or tissues after local injection of nuclide labeled TH-SC01 cells.

    Based on the image data obtained by PET/CT scan, OLINDA's sphere model was used to delineate the injection site and important organs or tissues as areas of interest (ROI), obtain standardized uptake values (SUV) of each ROI, and obtain time-radioactive activity curves (TACs) of each tissue and organ. The absorbed dose of vital organs or tissues, the equivalent dose of the whole body, and the distribution and change of transplanted cells in different tissues or organs at different time points are described

    Time frame: Week 1

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Apr 2024 (actual). Primary completion is estimated for Nov 2024, 7 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
May 9, 2024
First posted
May 24, 2024
StartActual
Apr 8, 2024
Primary completionEst.
Nov 2024
CompletionEst.
Dec 2025
Last update
Jun 12, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 12, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06429241
Lead sponsor
Jiangsu Topcel-KH Pharmaceutical Co., Ltd.
Responsible party
Sponsor
First posted
May 24, 2024
Start date
Apr 8, 2024
Primary completion
Nov 2024 (estimated)
Completion
Dec 2025 (estimated)
Last update
Jun 12, 2024

Study contacts

Miu Li Yan The First Affiliated Hospital of Soochow University
Contact
E-mail:sdfyec@163.com
86+0512-67972858

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion